Plain-English translation of NCT07502560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers want to know if Shingrix, a vaccine that protects against shingles (a painful viral infection), might also help prevent dementia. This study will give some older adults the vaccine and others a placebo (a dummy shot), then track whether fewer people in the vaccine group develop dementia over time.
Some research suggests that shingles infections may be linked to dementia risk. This trial is testing whether preventing shingles with this medication could also reduce the chance of developing dementia in older adults.
You likely qualify if…
You likely don't qualify if…
You would receive two shots: the first at your first visit and the second between 2 and 6 months later. Three out of four participants receive the actual vaccine, while one out of four receive a placebo. Researchers will then track your health records over time to see if you develop dementia, comparing outcomes between the two groups.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Finland